Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gianantonio Rosti

Showing results (21-30 of 153) with videos related to

Pageof 16
Sort By:
Leukemia|January 25, 2019
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overviewMichele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, et al.
Biologics : Targets & Therapy|August 27, 2009
Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intoleranceGiovanni Martinelli, Ilaria Iacobucci, Simona Soverini, et al.
Drugs|April 9, 2014
First-line treatment of newly diagnosed elderly patients with chronic myeloid leukemia: current and emerging strategiesGabriele Gugliotta, Fausto Castagnetti, Michela Apolinari, et al.
European Journal of Clinical Investigation|May 3, 2012
Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemiaFrancis Giles, François-Xavier Mahon, Bjorn Gjertsen, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 28, 2020
Outcome of Imatinib Treatment in Yemeni Patients With Chronic Myeloid Leukemia and the Influence of Nonadherence to Treatment and Duration of Previous Hydroxyurea TherapyJameel Al-Ghazaly, Waled Al-Dubai, Yousr Noaman, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 25, 2016
Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapiesFabio Efficace, Massimo Breccia, Francesco Cottone, et al.
Leukemia Research|August 3, 2013
Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitorsFabio Efficace, Gianantonio Rosti, Francesco Cottone, et al.
Health and Quality of Life Outcomes|October 20, 2017
Physicians' attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patientsMassimo Breccia, Michele Baccarani, Gianantonio Rosti, et al.
Oncotarget|November 21, 2017
Chibby 1: a new component of β-catenin-signaling in chronic myeloid leukemiaManuela Mancini, Simona Soverini, Gabriele Gugliotta, et al.
Blood|March 7, 2008
The effects of imatinib on pregnancy outcomeSeonaid M Pye, Jorge Cortes, Patricia Ault, et al.
Pageof 16

Showing results (21-30 of 153) with videos related to

Sort By:
Pageof 16
Leukemia|January 25, 2019
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overviewMichele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, et al.
Biologics : Targets & Therapy|August 27, 2009
Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intoleranceGiovanni Martinelli, Ilaria Iacobucci, Simona Soverini, et al.
Drugs|April 9, 2014
First-line treatment of newly diagnosed elderly patients with chronic myeloid leukemia: current and emerging strategiesGabriele Gugliotta, Fausto Castagnetti, Michela Apolinari, et al.
European Journal of Clinical Investigation|May 3, 2012
Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemiaFrancis Giles, François-Xavier Mahon, Bjorn Gjertsen, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 28, 2020
Outcome of Imatinib Treatment in Yemeni Patients With Chronic Myeloid Leukemia and the Influence of Nonadherence to Treatment and Duration of Previous Hydroxyurea TherapyJameel Al-Ghazaly, Waled Al-Dubai, Yousr Noaman, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 25, 2016
Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapiesFabio Efficace, Massimo Breccia, Francesco Cottone, et al.
Leukemia Research|August 3, 2013
Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitorsFabio Efficace, Gianantonio Rosti, Francesco Cottone, et al.
Health and Quality of Life Outcomes|October 20, 2017
Physicians' attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patientsMassimo Breccia, Michele Baccarani, Gianantonio Rosti, et al.
Oncotarget|November 21, 2017
Chibby 1: a new component of β-catenin-signaling in chronic myeloid leukemiaManuela Mancini, Simona Soverini, Gabriele Gugliotta, et al.
Blood|March 7, 2008
The effects of imatinib on pregnancy outcomeSeonaid M Pye, Jorge Cortes, Patricia Ault, et al.
Pageof 16